News

Roche's phase III IMmotion151 study of Tecentriq & Avastin to treat advanced/metastatic RCC meets co-primary endpoint

Harbour BioMed to present phase II data of HBM4003 & tislelizumab combination in MSS metastatic colorectal cancer at ESMO 2025

Cambridge, Massachusetts

Friday, August 1, 2025, 18:00 Hrs [IST]

Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced that it will present phase II clinical data on

To access the full article, please log in or subscribe.

Pharma Services

Tenders & Projects

Tenders & Enquires Pharma Projects

Corporate

Company Profile Corporate Results Corporate X-ray Pharmabiz Studies of Top Companies

US FDA Update

US FDA: ANDA US FDA: Warnings US FDA: Approved NMEs US FDA: Approved NMEs US FDA: REFUSAL

Export & Import

Drug Export Procedures Drug Units With WHO GMP Certification Pharma Export Data Import Reg. Update

Pharma Laws & Documents

Notifications Pharma Regulations Patent Laws and Amendments Patent Scan Documents New Drug Approvals Notified Prices

Labs & Govt Bodies

Govt Recognised In-House R&D Units AICTE Boards & Committees List of Indian CROs List of CROs (International) Govt & approved labs of India List of State Drugs Controllers